Inhibrx Biosciences Inc
INBX
查看详细走势图
83.910USD
+2.380+2.92%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.22B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.92%
5天
+10.02%
1月
+10.51%
6月
+293.21%
今年开始到现在
+6.22%
1年
+565.95%
查看详细走势图
TradingKey Inhibrx Biosciences Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Inhibrx Biosciences Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名110/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价12.00。中期看，股价处于平稳状态。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Inhibrx Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Inhibrx Biosciences Inc亮点
亮点风险
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
业绩增长期
公司处于发展阶段，最新年度总收入200.00K美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值低估
公司最新PE估值-7.01，处于3年历史低位
机构减仓
最新机构持股9.80M股，环比减少14.27%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值12.54K
分析师目标
根据
1
位分析师
持有
评级
12.000
目标均价
-49.87%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Inhibrx Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Inhibrx Biosciences Inc简介
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
公司代码INBX
公司Inhibrx Biosciences Inc
CEOLappe (Mark P)
网址https://inhibrx.com/
相关品种
